FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old
The FDA has authorized COVID-19 shots from Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)/ BioNTech SE (NASDAQ: BNTX) targeting the original coronavirus and Omicron sub-variants for use in children as young as six months of age.
The amended authorization allows the use of Moderna's bivalent shot as a booster in children six months through 5 years of age, two months after their initial vaccination.
Pfizer/BioNTech's updated shot can now be given as a third dose to those aged six months through 4 years who have not completed their primary vaccination series or are yet to receive the third dose.
Related: Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims.
The agency said that children who have completed their initial three-dose vaccination with Pfizer's original shot are not yet eligible to receive the bivalent booster.
FDA said that data supporting Pfizer/BioNtech's bivalent shot as a booster for children aged six months - 4 years is expected in January.
Price Action: PFE stock is up 2.23% at $51.36, BNTX shares are up 3.78% at $168.78, and MRNA shares are up 1.73% at $182.09 on the last check Thursday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
